AUTHOR=Xu Bingyang , Xu Zining , Ye Shuhong , Sun Hong , Zhao Bin , Wu Na , Wu Jiawen 

TITLE=JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

JOURNAL=Frontiers in Medicine

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1239869

DOI=10.3389/fmed.2023.1239869

ISSN=2296-858X

ABSTRACT=<sec id="sec1"><title>Background</title><p>Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.</p></sec><sec id="sec2"><title>Objective</title><p>To observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.</p></sec><sec id="sec3"><title>Methods</title><p>Four Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.</p></sec><sec id="sec4"><title>Results</title><p>Abrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.</p></sec><sec id="sec5"><title>Conclusion</title><p>The JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.</p></sec>